Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals, Inc.
  6. News
  7. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
597.62 USD   +0.54%
07:52aRegeneron Says its EYLEA Injection Supplemental Biologics License Application Has Been Accepted by the US FDA for Review
MT
06:24aREGENERON : FDA to Review Extended Eylea Regimen in Diabetic Retinopathy
DJ
06/27Intellia and regeneron present updated interim data from phase 1 study of crispr-based ntla-2001 for the treatment of transthyretin
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target

05/23/2022 | 09:58am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
07:52aRegeneron Says its EYLEA Injection Supplemental Biologics License Application Has Been ..
MT
06:24aREGENERON : FDA to Review Extended Eylea Regimen in Diabetic Retinopathy
DJ
06/27Intellia and regeneron present updated interim data from phase 1 study of crispr-based ..
AQ
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Tra..
MT
06/24Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Po..
CI
06/24Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based ..
AQ
06/24REGENERON PHARMACEUTICALS, INC.(NASD : REGN) added to Russell 1000 Dynamic Index
CI
06/15REGENERON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 756 M - -
Net income 2022 4 039 M - -
Net cash 2022 8 626 M - -
P/E ratio 2022 16,3x
Yield 2022 -
Capitalization 64 046 M 64 046 M -
EV / Sales 2022 4,71x
EV / Sales 2023 4,12x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 597,62 $
Average target price 679,24 $
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-5.87%64 046
GILEAD SCIENCES, INC.-14.32%78 031
VERTEX PHARMACEUTICALS25.76%70 632
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979
GENMAB A/S-14.75%20 761